These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 29920743)
21. The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura. Starke R; Machin S; Scully M; Purdy G; Mackie I Br J Haematol; 2007 Feb; 136(4):649-55. PubMed ID: 17367414 [TBL] [Abstract][Full Text] [Related]
22. ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies. Tersteeg C; Verhenne S; Roose E; Schelpe AS; Deckmyn H; De Meyer SF; Vanhoorelbeke K Expert Rev Hematol; 2016; 9(2):209-21. PubMed ID: 26581428 [TBL] [Abstract][Full Text] [Related]
23. The role of ADAMTS13 in the pathogenesis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. George JN Clin Adv Hematol Oncol; 2005 Aug; 3(8):627-32. PubMed ID: 16167049 [TBL] [Abstract][Full Text] [Related]
24. Generation of Anti-Murine ADAMTS13 Antibodies and Their Application in a Mouse Model for Acquired Thrombotic Thrombocytopenic Purpura. Deforche L; Tersteeg C; Roose E; Vandenbulcke A; Vandeputte N; Pareyn I; De Cock E; Rottensteiner H; Deckmyn H; De Meyer SF; Vanhoorelbeke K PLoS One; 2016; 11(8):e0160388. PubMed ID: 27479501 [TBL] [Abstract][Full Text] [Related]
25. Shear stress and von Willebrand factor in health and disease. Tsai HM Semin Thromb Hemost; 2003 Oct; 29(5):479-88. PubMed ID: 14631548 [TBL] [Abstract][Full Text] [Related]
26. Comparison of ADAMTS13 and Von Willebrand factor levels and activities, and plasminogen levels, in plasma products currently available for the treatment of thrombotic thrombocytopenic purpura in South Africa. van Marle AC; Joubert J; Meiring SM Transfus Apher Sci; 2019 Feb; 58(1):72-78. PubMed ID: 30551950 [TBL] [Abstract][Full Text] [Related]
27. Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura. Tersteeg C; Schiviz A; De Meyer SF; Plaimauer B; Scheiflinger F; Rottensteiner H; Vanhoorelbeke K Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2336-42. PubMed ID: 26338302 [TBL] [Abstract][Full Text] [Related]
28. High-resolution epitope mapping by HX MS reveals the pathogenic mechanism and a possible therapy for autoimmune TTP syndrome. Casina VC; Hu W; Mao JH; Lu RN; Hanby HA; Pickens B; Kan ZY; Lim WK; Mayne L; Ostertag EM; Kacir S; Siegel DL; Englander SW; Zheng XL Proc Natl Acad Sci U S A; 2015 Aug; 112(31):9620-5. PubMed ID: 26203127 [TBL] [Abstract][Full Text] [Related]
29. Degradation of two novel congenital TTP ADAMTS13 mutants by the cell proteasome prevents ADAMTS13 secretion. Underwood M; Peyvandi F; Garagiola I; Machin S; Mackie I Thromb Res; 2016 Nov; 147():16-23. PubMed ID: 27665541 [TBL] [Abstract][Full Text] [Related]
30. Insights into 3D Structure of ADAMTS13: A Stepping Stone towards Novel Therapeutic Treatment of Thrombotic Thrombocytopenic Purpura. Ercig B; Wichapong K; Reutelingsperger CPM; Vanhoorelbeke K; Voorberg J; Nicolaes GAF Thromb Haemost; 2018 Jan; 118(1):28-41. PubMed ID: 29304523 [TBL] [Abstract][Full Text] [Related]
31. The VWF/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction. Austin SK; Starke RD; Lawrie AS; Cohen H; Machin SJ; Mackie IJ Br J Haematol; 2008 May; 141(4):536-44. PubMed ID: 18341632 [TBL] [Abstract][Full Text] [Related]
32. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Tsai HM J Mol Med (Berl); 2002 Oct; 80(10):639-47. PubMed ID: 12395148 [TBL] [Abstract][Full Text] [Related]
33. Recent advances in thrombotic thrombocytopenic purpura. Sadler JE; Moake JL; Miyata T; George JN Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695 [TBL] [Abstract][Full Text] [Related]
34. ADAMTS13 missense variants associated with defective activity and secretion of ADAMTS13 in a patient with non-cirrhotic portal hypertension. Goel A; Raghupathy V; Amirtharaj GJ; Chapla A; Venkatraman A; Ramakrishna B; Ramachandran A; Thomas N; Balasubramanian KA; Mackie I; Elias E; Eapen CE Indian J Gastroenterol; 2017 Sep; 36(5):380-389. PubMed ID: 28980147 [TBL] [Abstract][Full Text] [Related]
35. Thrombospondin-1 and ADAMTS13 competitively bind to VWF A2 and A3 domains in vitro. Wang A; Liu F; Dong N; Ma Z; Zhang J; Su J; Zhao Y; Ruan C Thromb Res; 2010 Oct; 126(4):e260-5. PubMed ID: 20705333 [TBL] [Abstract][Full Text] [Related]
37. [From gene to disease; congenital thrombotic thrombocytopenic purpura due to mutations in the ADAMTS13 gene]. Schiphorst RH; van de Kar NC; van den Heuvel LP Ned Tijdschr Geneeskd; 2003 Dec; 147(49):2422-4. PubMed ID: 14694551 [TBL] [Abstract][Full Text] [Related]
38. [Genetic polymorphism of von Willebrand factor (VWF)-cleaving protease, ADAMTS13]. Kokame K Brain Nerve; 2008 Nov; 60(11):1325-32. PubMed ID: 19069166 [TBL] [Abstract][Full Text] [Related]
39. Plasmin Cleaves Von Willebrand Factor at K1491-R1492 in the A1-A2 Linker Region in a Shear- and Glycan-Dependent Manner In Vitro. Brophy TM; Ward SE; McGimsey TR; Schneppenheim S; Drakeford C; O'Sullivan JM; Chion A; Budde U; O'Donnell JS Arterioscler Thromb Vasc Biol; 2017 May; 37(5):845-855. PubMed ID: 28279966 [TBL] [Abstract][Full Text] [Related]
40. An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutations. Zhou W; Tsai HM Thromb Haemost; 2004 Apr; 91(4):806-11. PubMed ID: 15045144 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]